Advances in Cancer Immunotherapy: From Bench to Bedside and Back

As cancer immunotherapies become more widely studied and clinically applied, it is increasingly important that clinical oncologists gain a sound understanding of the relevant immunologic principles. There is a wave of new immunotherapy treatments for patients that clinicians need education on how they work, side effects, efficacy, and important questions. To ensure effective translation of cancer immunotherapy advances to the clinical arena, it is critical that community oncologists are educated on the foundations of tumor immunology and mechanisms of immune activation and inhibition. To improve outcomes of patients with cancer, clinical oncologists must be well-informed on recent advances in cancer immunotherapies and biologic treatments.

Given rapidly emerging scientific and clinical advances, there is a need for an integrated tumor immunology/immunotherapy course 1) to provide clinical oncologists with a robust framework for understanding the principles of cancer immunology/immunotherapy; and 2) to promote appropriate clinical application of cancer immunotherapies, how they work, the side effects and the efficacy to improve patient outcomes.
+ show speakers and program
Program Organizers:
Thomas F. Gajewski, MD, PhD - University of Chicago
Justin Kline, MD - University of Chicago

Program Directors:
F. Stephen Hodi, MD - Dana-Farber Cancer Institute
Howard Kaufman, MD, FACS - Rush University Medical Center

31 May - 31 May 2013
chicago
United States of America
meeting website